Pseudomonas aeruginosa diagnosis A new approach for the diagnosis of Pseudomonas aeruginosa infections

  • Edition: 2016
  • Research center: Nanobiotechnology for Diagnostics group
  • Scientific Area: Clinical sciences
  • Business area: Diagnostic
  • Status: In development
  • Contact: miriam.corredor@iqac.csic.es

Pseudomonas aeruginosa (PA) is a life-threatening pathogen, which is frequently implicated in healthcare-associated infections (HAIs), particularly in critically ill or immunocompromised patients. Moreover, the emergence of multiple drug resistant microorganisms has become a major hurdle for effective treatments after infections caused by PA. In the Nb4D a novel immunodiagnostic test for the rapid detection of pyocyanin, a specific virulence factor sectreted by P. aeruginosa has been developed as a biomarker for this type of infection. 

Goals

  • To perform the clinical validation of the ELISA assay for the detection of P. aeruginosa infections in different respiratory samples. This would render a faster  and reliable diangostic of P. aeruginosa infections opening the possibility to apply more appropriate specific treatment.  

Problem to Solve

P. aeruginosa is an opportunistic and life-threatening pathogen, with a high percentage of mortality incidence. The selection of an appropriate treatment requires confirmatory laboratory tests, which take more than 24 hours. The delay in diagnosis and therefore treatment onset increases both healthcare expenditure and the length of the treatments, as well as an increase in thedrug resistance of the microorganisms.

Innovation

The immunochemical assay developed is specific of Pseudomonas aeruginosa, highly sensitive, robust, reproducible and provides actionable results in less than 2 hours, allowing routine screening and simultaneous analysis of multiple samples.

Level of Innovation

The current gold standard for pathogen identification relies on bacterial culture, which requires enrichment steps on specific growth media to reach detectability. The delay in time and limitations regarding sensitivity, have major effects in the positive outcomes of patients. Thus, the proposed approach would greatly enhance the diagnosis giving actionable information to clinicians on whether to start the appropriate treatment.

Team

PhD. Promotion manager

Miriam Corredor

Nanobiotechnology for Diagnostics group

Head

Prof. M.Pilar Marco

Nanobiotechnology for Diagnostics group

PhD. Manager

Lluisa Vilaplana

Nanobiotechnology for Diagnostics group

Ph.D. Knowledge Transfer Manager

Isabel Masip

Institut de Química Avançada de Catalunya

Ph.D. Head of Microbiology and Parasitology Service

Tomas Pumarola

the Hospital Vall d’Hebron

Partners

Obra Social
Caixa Capital Risc